- $948.24m
- $487.03m
Aerovate Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Aerovate Therapeutics Announces First Quarter Financial Results And Business Highlights
Brief: Aerovate Therapeutics posts Q1 basic EPS USD -0.67
Brief: Aerovate Therapeutics Inc - Entered Into ATM Equity Offering Sales Agreement With Bofa Securities With Respect To At--Market Offering Program
Brief: Aerovate Therapeutics Reports Q4 Basic EPS of USD -0.61.
Brief: Aerovate Therapeutics Announces Full-Year Financial Results
Brief: Aerovate Therapeutics Appoints Donald Santel To Its Board Of Directors
Brief: Aerovate Therapeutics Publishes Results Of Phase 1 Study Evaluating AV-101 For The Treatment Of Pulmonary Arterial Hypertension In ERJ Open Research
Brief: Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
Brief: Aerovate Therapeutics Presents Novel Phase 2B/Phase 3 IMPAHCT Trial Design
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Coupa Software, Docusign
Brief: Aerovate Therapeutics Files For Mixed Shelf Of Up To $300 Million
Brief: Aerovate Therapeutics reports Q2 results
Brief: Aerovate Therapeutics Presents Phase 1 Data For Pulmonary Arterial Hypertension Treatment
Brief: Aerovate Therapeutics Announces First Quarter 2022 Financial Results
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:45 AM
U.S. RESEARCH ROUNDUP-Ambarella, Carpenter Technology, Morphic Holding
U.S. STOCKS ON THE MOVE-Adobe, Under Armour, Lennar, gold stocks
Brief: Aerovate Therapeutics Announces Initiation Of Impahct Phase 2B/Phase 3 Trial Of Av-101 In Pulmonary Arterial Hypertension